0000000000802767

AUTHOR

Dorota Borys

showing 2 related works from this author

Effects of prophylactic ibuprofen and paracetamol administration on the immunogenicity and reactogenicity of the 10-valent pneumococcal non-typeableH…

2016

ABSTRACT Prophylactic paracetamol administration impacts vaccine immune response; this study (www.clinicaltrials.gov: NCT01235949) is the first to assess PHiD-CV immunogenicity following prophylactic ibuprofen administration. In this phase IV, multicenter, open-label, randomized, controlled, non-inferiority study in Romania (November 2010–December 2012), healthy infants were randomized 3:3:3:1:1:1 to prophylactically receive immediate, delayed or no ibuprofen (IIBU, DIBU, NIBU) or paracetamol (IPARA, DPARA, NPARA) after each of 3 primary doses (PHiD-CV at age 3/4/5 months co-administered with DTPa-HBV-IPV/Hib at 3/5 and DTPa-IPV/Hib at 4 months) or booster dose (PHiD-CV and DTPa-HBV-IPV/Hib…

Malemedicine.medical_specialtyAntipyreticsparacetamolImmunologyIbuprofenBooster doseDiphtheria-Tetanus-acellular Pertussis Vaccinesmedicine.disease_causeGastroenterologyHaemophilus influenzaePneumococcal Vaccines03 medical and health sciences0302 clinical medicinevaccine030225 pediatricsInternal medicinemedicineHumansImmunology and Allergy030212 general & internal medicineAntipyretic10-valent pneumococcal conjugateAcetaminophenfeverPharmacologyReactogenicityRomaniabusiness.industryIncidenceorganic chemicalsImmunogenicityInfantIbuprofenResearch PapersAntibodies BacterialHealthy VolunteersAcetaminophenVaccinationTreatment OutcomeImmunologyFemaleprophylaxisbusinessmedicine.drugHuman Vaccines & Immunotherapeutics
researchProduct

Induction of immunologic memory following primary vaccination with the 10-valent pneumococcal nontypeable Haemophilus influenzae protein D conjugate …

2011

Background Induction of immunologic memory was assessed following primary vaccination with 10-valent pneumococcal nontypeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV). Methods Infants were randomized (1:1) to receive 3 doses of PHiD-CV or 7vCRM (7-valent CRM197-conjugated pneumococcal conjugate vaccine [PCV]) at 2, 3, and 4 months of age followed by 23-valent pneumococcal polysaccharide vaccine (23vPS) booster dose at 11 to 14 months of age. Pneumococcal geometric mean antibody concentrations (GMCs) and opsonophagocytic activity (OPA) geometric mean titers were measured. Results Postprimary immune responses were consistent with those in previous PHiD-CV and 7vCRM studies…

Microbiology (medical)Heptavalent Pneumococcal Conjugate VaccineImmunization SecondaryBooster dosemedicine.disease_causecomplex mixturesPneumococcal conjugate vaccinePneumococcal InfectionsHaemophilus influenzaePneumococcal VaccinesConjugate vaccinemedicineHeptavalent Pneumococcal Conjugate VaccineHumansHepatitis B VaccinesVaccines CombinedDiphtheria-Tetanus-Pertussis VaccineImmunization ScheduleHaemophilus VaccinesVaccines Conjugatebusiness.industryVaccinationInfantOpsonin ProteinsPneumococcal polysaccharide vaccineAntibodies BacterialVaccinationPoliovirus Vaccine InactivatedInfectious DiseasesStreptococcus pneumoniaeTreatment OutcomeImmunizationPediatrics Perinatology and Child HealthImmunologybusinessImmunologic Memorymedicine.drugThe Pediatric infectious disease journal
researchProduct